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Uremia is the clinical consequence of poor renal
function and is also the target of hemodialysis (HD)
therapy. In the absence of a comprehensive understand-
ing of uremia, the optimum therapy for an average
patient with end-stage renal disease (ESRD) can be
discovered by observing outcomes during a large clinical
trial with randomly assigned dialysis options. The
HEMO study was an ambitious effort to bypass
traditional studies of disease pathogenesis (uremia) in
favorof this typeofpopulation study (1). Themotivation
for embarking upon a population study like HEMO has
been the persistently high HD mortality rate in the
United States over the past 15 years (2).
Most clinical trials are tests of drug therapieswhere the
primary goal is to determine whether or not the drug in
question works, that is, whether treatment with the drug
is better than treatment with a placebo. In contrast, the
HEMO investigatorswere not hoping for a response, but
had true equipoise, meaning that they were equally
willing to accept a negative or positive response. In
statistical terms, they were equally willing to accept or to
reject the null hypothesis, which in this case was that the
high dose of dialysis and/or high membrane flux would
not have an effect. Potential benefits could be realized
with either outcome, so ‘‘failure’’ of such a study only
occurs when the outcome is equivocal, perhaps suggest-
ing an effect but with no definite conclusion.
The HEMO study results were not equivocal, so the
study can be viewed by all participants, patients,
investigators, the dialysis industry, and the public in
general as a resounding success. The study clearly
demonstrated the futility of recent popular attempts to
push the dose of dialysis beyond the Dialysis Outcomes
Quality Initiative (DOQI) recommendedminimum limit.
Prior to the HEMO study, the minimum targeted dose,
expressed as a single-pool Kt/V of 1.30 per dialysis
treatment administered three times a week, was derived
froma consensus of practicing nephrologists (3).Now, in
addition to this learned opinion of nephrologists, the
HEMO clinical trial provides objective evidence that the
previously established minimum dose is also the opti-
mum dose (4). In addition, the HEMO study shows us
that improving the clearance of large molecules (inde-
pendent of small molecules) by using high-flux mem-
branes does not improve the survival of the average
patient. Both of these observations have far-reaching
implications with regard to the pathogenesis of uremia
and its treatment.
Applicability of the Study
Therapeutic decisions based on data from the HEMO
study should be made with an awareness of the type of
patient included in the study, the outcomes that were
monitored, and which outcomes were preselected (a
priori) for study. Although several entry criteria were
applied before patients were enrolled, these entry limits
were primarily intended to improve the power of the
study to distinguish an effect, using death as the primary
outcome (5). Excluded patients were highly likely to die
from causes other than inadequate dialysis (e.g., from
cancer). The resulting randomized population had
clinical characteristics that were representative of a cross
section of patients currently dialyzed in the United
States.
Nephrologists are sensitive to the quality as well as the
quantity of life when deciding to begin, continue, or
change dialysis treatments. Patient survival was the
primary outcome criterion, but several clinically import-
ant secondary outcomes were also carefully monitored
from the beginning of the HEMO study. First hospital-
izations for cardiovascular events, first hospitalizations
for infection, all nonaccess-related hospitalizations, and
a 15% decline in serum albumin concentration from
baseline were predesignated as secondary outcome
monitors. For the first three secondary outcomes, all-
cause mortality was included to increase the power. In
addition, prior to beginning the full-scale study, the
principal investigators selected seven additional variables
for scrutiny because they appeared to influence patient
outcomes in previous studies. These variables were the
patient’s age, gender, race, diabetes as a cause of ESRD,
number of years on dialysis when enrolled, baseline
serum albumin, and an index of comorbidity. The
importance of preselection and limiting the number of
variables has been emphasized (1).
Value of Clinical Trials
Although expensive, clinical trials add a degree of
certainty to treatment options that is not possible with
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othermethods. Studies basedonobservation alone suffer
from an inability to distinguish cause from effect. A
recent example can be found in the correlation between
cardiovascular disease and postmenopausal hormone
replacement (6). The correlation between dialysis dose
and survival seen in previous observational studies based
onMedicare dataor registries fromother countries could
have resulted from an inability to deliver higher doses to
patients who are near death or from some other
characteristic of patients at risk for death that also
interfered with delivery of dialysis. By assigning patients
randomly to treatment options in a clinical trial such as
theHEMOstudy, thepossibilityof reverse causationwas
eliminated. Random assignments with an intention-
to-treat analysis are key to avoidingmisinterpretation of
the data.
HD Dose
Separation of the dose groups took a major effort on
the part of the individual dialysis center coordinators and
the data coordinating center where statisticians carefully
monitored the data and kept each coordinator informed
about patients who strayed from their randomized
assignments. In the end, the separation was especially
good, with less than 5% overlap in the target treatment
eKt/V values (7). This means that the lack of response to
the higher dose cannot be attributed to poor separation
of the mean target values nor to inattentiveness on the
part of the centers to keep each patient within his or her
designated target throughout the study.
Nephrologists in general pay attention to the dialysis
climate and respond quickly. Evidence of this can be
found in the gradual increase in mean Kt/V that has
occurred in the United States over the past 10 years. The
average single-pool Kt/V has increased from approxi-
mately 1.10 in 1992 at the beginning of theHEMO study
to 1.49 per dialysis in 2001 (2). Perhaps enthusiasm
expressed by HEMO workers trying to recruit patients
was misinterpreted by non-HEMO providers as a sign
that the authorities supported increasing the dose to
levels approaching the high goal of the HEMO study.
The decision to publish individual clinic outcomes on the
Internet, including the average dose of dialysis achieved
in each dialysis clinic, probably contributed to this
upward trend. During the early 1990s the mortality rate
decreased, perhaps because of a reduction in the number
of patients who were well below the threshold minimum
value (8). But since 1995, despite a significant increase in
averageKt/V, no improvement in survival is evident even
when the data are adjusted for age, diabetes, and other
comorbid factors (2).
These observations, now supported by the HEMO
study, indicate that for patients treated three times a
week, a ceiling has been reached for the benefits
expected by increasing the dose. The HEMO study
also showed that this ceiling, the dose threshold above
which improvements in mortality cannot be expected,
is lower than some of the cross-sectional analyses had
previously shown, and is possibly lower in men than in
women (9).
Concentration-Dependent Toxicity
The question, ‘‘Why does giving more dialysis not
help the patient?’’ requires a review of basic concepts.
The concept that uremia, the target of dialysis, is a
toxic state caused by accumulation of dialyzable
solutes is fundamental. The severity of uremia must
therefore correlate with the level of toxins in the body,
which are presumably water soluble compounds found
in the blood, the only tissue to which the dialyzer has
access. For reasons that have been extensively
reviewed and accepted (which I will not review here),
nephrologists, including the HEMO investigators, have
chosen the clearance of an easily dialyzable solute
(urea) as the best measure of dialysis dose. However,
even for continuous dialysis, clearance does not
correlate linearly with (is not proportional to) solute
levels. The concentration of creatinine, for example, is
a hyperbolic function of native kidney clearance, a
relationship well known to practicing nephrologists.
Furthermore, the concentration of a toxin does not
usually correlate linearly with its toxic effect, including
death. Animal studies have shown that for known
lethal toxins, this relationship is most often sigmoidal,
with a threshold toxic level above which animals begin
to die and a threshold lethal level above which all
animals die (10). Applying these nonlinear relation-
ships to intermittent treatments where rapidly chan-
ging concentrations reduce clearance efficiency, the
curvilinear relationship between clearance and mortal-
ity is enhanced. When these concepts are combined
and applied to the HEMO study, one can image how
the dose/mortality curve reaches a plateau above
which no further benefits can be extracted.
Recognizing theproblemwithureadisequilibrium, the
HEMO investigators decided from the beginning to use
eKt/V instead of the traditional single-pool Kt/V as the
adequacy index (7).Use of eKt/V tended to straighten the
relationship between mortality and dose, but only with
respect to urea and only with regard to the relationship
between patient clearance and dialyzer clearance. Other
solutes maintain a curvilinear relationship between
patient and dialyzer clearance and none of the other
nonlinear relationships listed abovewere straightened by
use of eKt/V (7).
Membrane Flux
The other arm of the HEMO study was a random
allocation of the same patients to treatment with either a
standard-flux or a high-flux dialyzer. The flux distinction
is actually a separation based on the clearance of high
molecular weight (MW) solutes. Thus the HEMO study
actually tested the effects of high and low clearances of
high and lowMW solutes. Of note, the clearance of high
MW solutes can be completely separated from clearance
of low MW solutes by selection of dialyzers. The
dialyzers chosen may have had similar clearances of
low MW solutes but markedly different clearances of
b2-microglobulin (b2M), the marker for high MW
solutes. Separation of clearances in the high MW range
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became a moving target to some extent as the study
progressed because of reuse practices that increased or
decreased the flux (11).
All dialysis membranes were either synthetic or made
from cellulose derivatives that were relatively biocom-
patible, meaning that the effect of pure cellulosic
complement-activating membranes was not tested.
Although the latter type of dialyzer/membrane was in
common use when the study started, the study investi-
gators anticipated that use would drastically decline in
later years, and this proved to be the case.
Absence of a significant reduction in mortality in the
high-flux group can be translated to absence of an
adverse effect of low-flux dialyzers. Trends in the
secondary analyses, however, suggested a beneficial
effect, andmortality appeared to be improved in patients
with high vintage at baseline. High vintage patients were
those maintained with HD for more than 3.7 years prior
to randomizations. Conclusions about the latter await
further analyses. The combined observations of border-
line significant reductions in mortality and cardiovascu-
lar deaths in all patients, and significant improvement in
survival in the high-vintage group should cause one to
pause and consider high-flux membranes, especially
today when the difference in cost of high-flux compared
to standard membranes has narrowed.
Subgroup Analysis
Subgroup analyses are not yet complete, but there was
a suggestion of a survival benefit at the higher dose in
women and a suggestion of a benefit from high-flux
dialysis in high vintage. For large subgroups, for
example, men versus women or large racial groups, the
outcome of the randomized groups cannot stray very far
from themean that showed no difference. The study was
relatively large, however, and powered at 84% probab-
ility to detect a 25% reduction in mortality, so small
differences can be significant. These subgroup reports
will continue to appear and their significance will be
debated with respect to clinical application and patho-
genesis. The clinician should remember, however, that
for the average patient neither mortality nor hospital-
ization rates, as defined by the four secondary outcome
criteria, were improved by either the high-dose or high-
flux treatments. This means that large benefits from high
dialyzer clearances of either large or small molecules in
selected large subsets of patients cannot be expected
when treatment is delivered in the present mode.
Limitations of the Study
As mentioned above, one must understand how the
HEMO study was conducted before making decisions
about individual patients. First, the patients were all
dialyzed within a treatment time window of 2.5–4.5
hours. Because no discernible difference in outcome
could be detected within these time constraints, it is
unlikely that slight increases in treatment time would
benefit the patient, but it is impossible to say whether
giving much longer treatments (e.g., 8 hours) might
confer a benefit. Second, the HEMO patients were all
given three treatments per week, so recent reports of
improved outcome in patients dialyzed more frequently
are not inconsistent with the HEMO study results. As
discussed above, the intermittent nature of HD, as
currently administered three times a week, is a major
contributor to the curvilinear nature of the dose
response, so increasing the frequency might be expected
tohelp.Third, all hemodialyzerswere reusedamaximum
of 20 times, so any adverse effect of reuse must be
considered part of the outcome and cannot be distin-
guished from the dose effect.
Patient Risks
A strong note of thanks should go out to the
patients who participated in the study. They put
themselves at risk for the benefit of other patients.
Although major efforts were made to avoid underdi-
alysis, and in the end it appears that there was no
risk, that information was not available to the patients
during the study, so the decision to participate in each
individual case was truly a sacrifice that was reflected
in the consent forms signed by each patient. The
decision by each individual patient and referring
physician to participate in this study was made in
the face of several public statements by otherwise
well-meaning critics of the study advising against it
because of the potential risk. These statements,
published in nonscientific but widely distributed
periodicals as late as January 2002, made it more
difficult and expensive for the HEMO investigators to
recruit patients. My hat is off to the patients who
volunteered and accepted potential risks so that others
might benefit. I also salute the more than 100
nephrologists who supported the study by allowing
their patients to be randomized in the face of public
criticism. Perhaps this study will serve as an example
for potential critics of future studies to avoid the trap
of being swayed by public opinion before definitive
data are available.
Conclusion
TheHEMO study conclusively answered the question
of how much more dialysis should be given to patients
based on the clearance of small or large molecules. The
answer is that the current minimum standard for small
molecule clearance per dialysis three times a week,
factored for the patients volume of urea distribution, is
enough and that giving more doesn’t seem to help the
average patient. In addition, use of more porous
membranes to improve the clearance of larger molecules
provides only minimal benefit for the average patient
dialyzed three times a week. These results should not be
construed as justifying a reduction in the dose of dialysis
in all patients; continued adherence to the DOQI
standard of 1.3 volumes per dialysis three times a week
is recommended. Increasing the dose in women may
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provide a small benefit, but analysis of these data are not
yet complete. Acknowledging that different individuals
may have differing sensitivities to toxins and different
rates of toxin accumulation, in clinical settings where
specific symptoms or signs of uremia persist, the dose
should be increased. Uncontrolled studies continue to
suggest that increasing the frequencyofdialysismayoffer
some benefit, so additional studies of frequency, a
variable that was not addressed by the HEMO study,
seem warranted.
What about the future? Will we see a decrease in the
average dose as a result of this study? If a decrease in the
averagedoseofdialysis occurs, it shouldnot result froma
wholesale decrease in all patients, but rather from a
reduction in patients who are in the high range only. The
ultimate effect would be a reduction in the spread of
doses to a narrower dose window. Whether increasing
the dose in certain subgroups will provide benefits can
only be suggested by the HEMO study data and will
require confirmation by other studies. Results of the
HEMOstudy shouldnot lead to complacency.Mortality
remains high, especially in the United States, so dialysis
providers must continue to look for ways to improve
survival (i.e., to be dissatisfied with the practice of
continuing to do what we do now).
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This brief commentary reviews the HEMO study
outcome results from the perspective of the dialysis
dosing controversy over the 20 years since the National
Cooperative Dialysis Study (NCDS) was completed in
1981. It is important to note, however, that the HEMO
study has not yet been formally published and thus the
following comments are based only on the presentation
of main study results by Gary Eknoyan at the spring
National Kidney Foundation (NKF) meeting in Chi-
cago earlier this year (1).
The NCDS was a landmark study (2) and, prior to
HEMO, the only study of clinical outcome in hemodi-
alysis (HD) correlated to prospectively randomized
dialysis doses. In retrospect it was a tiny study of only
160 patients observed a minimum of 6 months and
distributed in four treatment arms, but it was a powerful
study because it was prospectively randomized and the
randomized doses were distributed over a very wide
range. Outcome in the NCDS was reported as the
probability of failure (PF), which was a global clinical
composite of de novo uremic symptoms, hospitaliza-
tions, and death occurring during follow-up.
Analysis of clinical outcome in the NCDS as a
function of spKt/V (3) is shown in Fig. 1, where the
probability of failure is normalized to the value at spKt/
V ¼ 1.45 and expressed as relative probability of failure
(RPF). The 10 groups with 16 patients in each group are
mapped toRPF and spKt/V coordinates in Fig. 1, where
the wide dispersion of both RPF (5.8 to 0.5) and spKt/V
(0.42 to 1.45) in the NCDS can be seen. Three highly
significant regressions of RPF on spKt/V were reported
(3) consisting of discontinuous, exponential, and linear
functions. Although it was not mathematically possible
to clearly show one relationship was superior to the
others, we felt the data conformed best to the discon-
tinuous function depicted in Fig. 1, which resulted in the
conclusion that optimal therapywas achieved with spKt/
V ‡ 1.0, a value 25% higher than the apparent break-
point at spKt/V ¼ 0.8. However, if RPF in the NCDS
were more correctly described by the exponential
regression shown in Fig. 1, a very significant decrease
in RPF would be predicted for spKt/V > 1.0. This
exponential curve would suggest a 70%decrease in RPF
if spKt/V were increased from 1.0 to 1.75.
Over the subsequent 20 years a number of observa-
tional studies have been reported suggesting the optimal
spKt/V is in the range 1.4–1.8 or even greater. Some of
Address correspondence to: Frank A. Gotch, MD, 144 Bel-
grave Ave., San Francisco, CA 94117, or email:
fgotchsf@cs.com.
Seminars in Dialysis—Vol 16, No 1 (January–February) 2003
pp. 11–13
HEMO STUDY IMPACT 11
these studies correlatedmortality tomean values of spKt/
V distributed over a wide range in the patient population
(4,5), calling into question the validity of using the mean
value (6). A very recent large observational study based
on dose estimates derived from the urea reduction ratio
(URR) suggests a linear decrease in mortality over all
doses observed up to an estimated spKt/V of 1.8 (7).
As noted above, the HEMO study was prospectively
randomized and had 10 times as many patients as the
NCDS,with observations extendingover up to 6 years of
follow-up compared to 6 months in the NCDS. Dr.
Eknoyan reportedmeandoses of spKt/Vof 1.32 and 1.71
(URR 66% and 75%) in the standard and high-goal
treatment arms, respectively. The details will un-
doubtedly be describedmuchmore fully in peer reviewed
publications by HEMO investigators. The higher doses
of dialysis did not improve survival, reduce hospitaliza-
tions, or maintain serum albumin. However, Dr. Ekno-
yan reported that in women the higher dose may have
been associated with improved survival, and further
analyses of this and other subgroups are under way.
The preliminary results for the HEMO study and the
very recent analysis of Health Care Financing Admin-
istration (HCFA) observational data (7) are shown
graphically inFig. 2 and are compared to the exponential
regression forNCDSdata inFig. 1. TheHEMOdata are
arbitrarily plotted for the standard and high-goal arms at
a relative risk of mortality (RRM) of 1.0, since there was
no change in mortality over the dose range studied. The
HCFA data (where dose was measured from URR) are
also plotted in Fig. 2 and indicate that RRM decreased
substantially as estimated spKt/V increased over the
range 1.0–1.7. It canbe seen inFig. 2 that outcomes in the
HEMO and HCFA studies are correlated to doses well
distributed over the controversial segments of the
discontinuous and exponential outcome curves for
the NCDS data in Fig. 1 and might be expected to
resolve the 20-year controversy.
These two studies are further compared in Fig. 3,
where RRM as a function of both URR and spKt/V are
shown. The striking differences between the two studies
are best illustrated here. In the HEMO study, when dose
was prospectively increased from spKt/V 1.31 to 1.75
with a corresponding URR increase from 66% to 75%,
there were no improvements in any clinical outcome
measures as noted above. Further, these two levels of
dosing were held constant for up to 6 years of follow-up.
In contrast, the HCFA data analysis over 1 year of
follow-up (but with many more patients and deaths
observed) showed a linear decrease in observed RRM
from1.0 to 0.76 as observedURR increased from67.5%
to77.5%.These observations led the authors to conclude
that adequatedialysis appears to require aURR > 75%
and spKt/V > 1.75. What can account for such strik-
ingly different results between the prospectively rand-
omized 6-year HEMO trial and the 1-year observational
analysis of HCFA data?
Onepartial explanation for thedifferencemay lie in the
relative reliability of dose measurement. The delivered
dose in the HEMO study was monitored monthly with
before and after blood urea nitrogen (BUN) levels
subjected to formal kinetic analysis to calculate the
delivered dose and change the prescription as needed to
maintain the targeted doses. In this way the frequency of
spurious URRs is reduced to near zero and URR
corresponds very closely with delivered spKt/V in each
individual patient. In contrast, the HCFA analysis is
based only on URR values reported to the nearest 5%
and there is no check on the validity of data. The most
commonerror inURRisalmost certainlyoverestimation
due to recirculation late in dialysis combined with faulty
technique in drawing the postdialysis sample. Such
processerrorscouldbeenhancedinsomedialysis facilities
under economic pressure and striving for maximal
URRs to report to the HCFA, and result in systematic
overestimationofURR,particularly in thehigher ranges.
Fig. 3. Comparison of RRMas f (URR) and f(spKt/V) in HCFA
and HEMO studies. See the text for a discussion.
Fig. 2. RRM in the HEMO study and in a recent HCFA study
compared to the HEMO and HCFA studies are targeted to the
controversial region of 1.0 £ spKt/V £ 1.7. See the text for a
discussion of these studies.
Fig. 1. The relative probability of failure (RPF) in the NCDS
(1985). The outcome data were interpreted to conform best to a
discontinuous function of spkt/V; however, an exponential fit was
also reported. Over the past 20 years these two interpretations have
been highly controversial over the range 1.0 £ spKt/Vk< 1.7.
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It is impossible to know how far the HCFA curves
might be displaced to the right in Fig. 3 due to some
systematic overestimation of URR values. URRs in the
range of 72.5–77.5% represent very high doses of dialysis
and, in the absence of kinetic validation of the delivered
dose, must be questioned. In the medium and large
patient groups, URRs of 72.5–77.5% were observed in
56% and 47% of patients, respectively, and correspond
roughly with spKt/V values of 1.6–1.8. Assuming an
averagevolumeof35Lfor themedium-sizedpatientsand
treatment time of 210 minutes, the dialyzer whole blood
clearances range from 310 to 355 ml/min. At an average
Qbof450ml/min, these clearanceswould requiredialyzer
whole bloodKoAs of 900–1400ml/min, higher thanmost
dialyzers readily available. Even higher clearances or
much longer treatment times would be required for large
patients, with 47% of URRs in the range 72.5–77.5%.
These considerations raise questions about the validity of
the high URR values in HCFA data that were not
subjected tokineticvalidationof thedose. In this regard it
is also important to emphasize that the HEMO study
provides the first data comparing clinical outcome
determined as a function of randomized doses accurately
measured by kinetic modeling to outcome correlated to
observed approximate measures of dose such as URR.
Another and perhaps more important reason for the
difference in the two studies is inherent in the nature of
randomized and observational studies. There may well
be unmeasured factors in the HCFA dataset that
influenced both URR and mortality that the investiga-
tors were unable to control for in the analysis. This type
of bias is unlikely in the HEMO study because patients
were randomized into the two Kt/V groups.
Is it possible that theHEMOstudywas not adequately
powered to rule out the magnitude of mortality decrease
observed in theHCFAdata?Over the range 1.33 £ spKt/
V £ 1.75 in the HCFA data, the RRM fell from 1.00 to
0.76, or 24%. The RRM for the Kt/V intervention in
HEMO was 0.96 (p ¼ 0.52) with 95% confidence limits
of 0.84–1.09 (16% reduction to 9% increase in RRM).
Thus the maximal possible benefit compatible with the
HEMO study results would be a 16% reduction in
RRM, which is inconsistent with the 24% reduction
observed in the HCFA data. The 95% confidence limits
on the four main secondary clinical composite outcomes
reported by Eknoyan (1) were very tight, with upper
bounds for the relative risk reduction of the high Kt/V
goal ranging from 9 to 13%, and provide further strong
evidence in support of thenull result in theHEMOstudy.
Although we must await full publication of the
HEMO study and subgroup analyses to reach final
conclusions, the outcome results reported to date are
very convincing that a kineticallymeasured spKt/Vof 1.3
and correspondingURRof 65%define the average fully
adequate dose of thrice weekly HD. However, in
individual patients with a range of treatment times and
ultrafiltration, the best definition of an adequate dose
would be an eKt/V of 1.2, the rounded up value that was
actuallymodeled and achieved in the standard arm.Both
spKt/V and URR may vary substantially in individual
patients relative to eKt/Vdue towide ranges of treatment
times and ultrafiltration. It should also be noted that the
average treatment times were 3.2 and 3.7 hours in the
standard and high goal arms and the shorter treatment
time had no adverse effect on outcome. Further analyses
of other observational data in conjunction with rand-
omized HEMO data may help to resolve the large
differences between the randomized and observational
studies that still persist.
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An oral report on theHEMO study at the 2002 spring
meetings of the National Kidney Foundation (NKF)
indicated no difference in mortality for patients rand-
omized to two dialysis dose groups of eKt/V ¼ 1.05
versus 1.45. This result has been a surprise tomany in the
renal community, including the expert panel of the
Dialysis Outcomes Quality Initiative (DOQI) guidelines
(1) whose information was based on several observa-
tional studies.
Randomized controlled clinical trials have several
design characteristics that avoid the biases that can occur
in observational studies. However, more details are
needed from the HEMO study before appropriate
conclusions can be reached about the following issues.
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What are the results? To date, the conclusions have
been stated as a failure to reject the null hypothesis of no
difference in outcomes for the two treatment groups or
that the outcomes were similar for both dialysis dose
study groups. However, standard textbooks indicate
that, ‘‘When the test statistic falls in the acceptance
region, we will not reject, rather than accept, the null
hypothesis. Further conclusions may be made by
calculating an interval estimate for the parameter…’’
(2). Thus such negative results should not be interpreted
as proof that there is no difference, but should instead be
interpreted based on a confidence interval range of
plausible differences in outcomes, which account for the
uncertainty in the data from the trial. The confidence
interval will clarify the size of the potential beneficial
effect in the higher-dose group.
How general are the results? Are there differences in
outcomes among subgroups of patients that preclude a
broad conclusion about all patients, as suggested in the
preliminary reports? Are there different means of
achieving a certain dose level that might be more
effective? The HEMO study does not offer definitive
conclusions about the efficacy (or lack of it) of the
achieved difference in Kt/V, but instead yields an
evaluation only of the specific protocols used to achieve
the differences in dialysis dose.
Randomized clinical trials have been rare in dialysis.
The last major trial in the United States, the National
CooperativeDialysis Study (NCDS),more than 20 years
ago, suggested that longer treatment time was associated
with better outcomes. However, since this finding had a
p-value of 0.056, it was considered not significant and
therefore not relevant (3). Subsequent analysis of the
same data byGotch and Sargent (4) led to the concept of
Kt/Vurea as an indicator of dialysis dose for small
molecules and as a predictor of outcomes.
Numerous observational studies have since confirmed
that low dialysis dose is associated with highermortality.
The DOQI guidelines, based on available evidence,
recommended aminimum single-poolKt/V of 1.2, which
corresponds to a double-pool or equilibrated eKt/V of
approximately 1.05 (1). Unresolved issues included
whether the dose should be substantially higher than
suggested by the DOQI and whether delivering the same
dose in a longer treatment time (t) would offer further
advantages to patients. Port et al. (5) showed that
patients treated with a URR > 75% had a lower
mortality risk than patients treated with a URR of
70–75%, on average. The 70–75% URR level is sub-
stantially above the recommended URR of greater than
65%. Given the current clinical practice of offering 3- to
4-hour dialysis on a thrice-weekly schedule, the effect of
varying treatment time is difficult to assess. However,
single-facility studies and the Dialysis Outcomes and
Practice Patterns Study (DOPPS) provide suggestive
evidence that delivering the same dose in sessions longer
than 4 hours is associated with lower mortality risk (6).
However, given the small sample size for these studies,
the p-value was greater than 0.10.
Thus evidence from several observational studies
suggested that for thrice-weekly hemodialysis (HD), a
greater dialysis dose is better. These findings have been
further corroborated with several reports on experience
after switching from standard to daily HD.Most reports
showed clear clinical advantages after the change tomore
frequent dialysis, whether it was delivered as long nightly
dialysis or short daytime dialysis (7). However, large
randomized trials regarding the frequency and duration
of dialysis are lacking.
The long-awaited results from theHEMOstudy failed
to confirm these findings from prior observational
studies overall. This new evidence may be confusing to
practicing clinicians. Randomized trials are usually
considered the ‘‘gold standard,’’ even when not blinded,
as was the case in the HEMO study.
There are importantdifferencesbetweenobservational
studies and randomized clinical trials (8). For example,
ethical reasons may prevent a trial to evaluate low-dose
HD, while observational studies can cover a wide range
of practices, including low doses. Cost issues demand
that clinical trials limit the sample size to a minimum
according topower calculations.Althoughobservational
studies suffer less from these limitations, their findings of
correlations are limited by confounding anddonot allow
for conclusions of causality. For example, if higher
dialysis doses are given to healthier patients, lack of
adjustment for the patient’s health status would not
permit differentiation of patient selection from a bene-
ficial effect of a higher dose. Therefore observational
studies need to strive to adjust for numerous potential
explanatory variables.
Randomized trials overcome the problem of con-
founding because the random assignment should make
all variables, except the one or two study factors, similar
in both groups. Occasionally some variables turn out to
be different by chance and, if recognized, statistical
adjustment can correct for such differences. Generaliz-
ability of the results depends on the exclusion of certain
patient groups, such as patients with high bodyweight in
the HEMO study. Large population-based observa-
tional studies are more likely to yield conclusions
applicable to the entire population.
With this background we can evaluate the currently
available evidence from the HEMO study. The primary
analysis showed no significant difference in outcomes
for the two dialysis-dose groups. This analysis used the
intention-to-treat approach according to the original
assignment. It will be important to know if the intended
dose separation for the two groupswas actually achieved
for all patients. Should there be a substantial overlap, the
negative results could be partially explained by lack of
power and misclassification of the dose groups. Secon-
dary analyses to evaluate the actually delivered dose and
correlate it with the outcomes can help to distinguish
between a failure to achieve desired protocols versus the
lack of an outcome difference between the protocols. Yet
such secondary analyses will reduce the benefit of
randomization, making ‘‘all else equal.’’
Patient selection for theHEMOstudy required that all
study patients could achieve the higher dose level of eKt/
V ¼ 1.45 before randomization. This requirement
excluded larger-sized patients so that body weights were
almost always less than 90 kg. This exclusion deserves
further exploration because of the ongoing debate about
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a J-shaped correlation of mortality risk by dialysis dose.
Body mass index (BMI) may serve as a proxy for
nutritional status. Based on data from Wolfe et al. (9),
BMI is correlated with body weight (likely because in
large populations weight varies more than height). Thus
the J-shape of an increase in risk at the highest dose levels
is largely explained by the confounding by body size, in
that smaller patients tend to receive a higher dose than
larger patients (9). Smaller patients are potentially
undernourished, which is clearly associated with higher
mortality (10). Recent data by BMI tertile suggest that
the exclusion of larger patients would not reduce the
expected association with mortality (5) and therefore
should not explain the negative finding in the HEMO
study.
Observational studies can be confounded by factors
that may explain the observed results. Therefore it is
critical for such studies to have a large sample size and to
adjust for numerous factors. Many of the studies (9)
adjusted for demographic factors, a large number of
comorbidities, and some laboratory values and showed
that a low dialysis dose was associated with higher
mortality risk.We should look for potential explanations
for the findings in the reports fromobservational studies.
Bias would arise if patients receiving a higher dose
were healthier to begin with than were those receiving
lower doses. Studies by Wolfe et al. (9) adjusted for
comorbid conditions at the beginning of the study. The
most recent study by Port et al. (5) adjusted for
comorbidities observed at an earlier time, yet the results
were consistent with a cross-sectional study that adjus-
ted for numerous comorbidities at the beginning of the
study. A more refined adjustment for severity of
comorbidity would reduce the potential for such bias,
but such adjustments are seldom perfect.
The measurement of dialysis dose is likely to be less
accurate in observational studies than in the HEMO
study, but this should have biased the observational
results to the null (i.e., to finding no difference) rather
than to finding significant and large differences in
mortality risk by dialysis dose. Similarly, observational
studies evaluated the baseline dose of dialysis, which
could change during follow-up, while the HEMO study
tried to maintain the delivered dose during follow-up.
Bias would arise in observational studies if better
doctors and teams deliver higher doses of eKt/V. Thus
better medical care rather than higher dose could have
led to the observed correlation. A recent study tried to
consider andminimize the role of other practice patterns:
Wolfe et al. (11) studied practices and outcomes at the
dialysis facility level rather than at the patient level. We
found that the adjusted mortality based on standardized
mortality ratio was higher in dialysis units that had a
larger fraction of their patients receiving suboptimal
URR of less than 65% or having a hematocrit of less
than 33% or using a central venous catheter. When
adjusting for these three practice factors simultaneously,
dialysis units with more patients receiving a low dialysis
dose still hadahigher standardizedmortality. Thuswhen
the practice of anemia and vascular access care was
similar, dialysis units that hada larger fractionofpatients
receiving a low dialysis dose had higher mortality.
In randomized clinical trials it is also possible that
other factors modified the results. Specifically, in the
unblinded study environment, other unmeasured factors
may have been given extra attention in the high-dose
group, which could reduce the expected difference in
outcomes and thus lead to a bias in the randomized trial.
The role of residual renal function needs to be
considered. There is evidence that residual renal function
plays an important role and that clearance of molecules
larger than urea is beneficial. Therefore it does not seem
appropriate to consider native renal function as equiv-
alent to dialysis clearance. Observational studies have
tried to overcome this problem by excluding to a large
extent patients with residual renal function—for exam-
ple, by starting the study after 15 months of dialysis
therapy (5). Observational studies suggest that higher
doses of dialysis are associatedwith lowermortality after
1 year of dialysis (after residual renal function has
declined), with only small effects during the first year of
dialysis. Presence of residual renal function in a study
groupwould limit generalizationof the results to patients
with little or no residual function.
Integration of the Discrepant Findings
for Clinical Practice
The low target dose for the HEMO study was
eKt/V ¼ 1.05, which corresponds approximately to a
single-poolKt/V of 1.2 and aURRof 65%.The target in
a trial must not be confused with amean value or goal in
clinical practice because the spread around the mean is
much wider in clinical practice than in a controlled study
environment. Therefore this study must not be inter-
preted to suggest that dialysis units reduce their target
dialysis dose to an eKt/V of 1.05. The target must be
substantially higher to ensure that all patients receive an
eKt/V of at least 1.05. Data for a lower eKt/V are only
available from observational studies and they are very
consistent in showing an association with higher mor-
bidity and mortality. Since even the high dialysis dose of
the HEMO study (eKt/V ¼ 1.45) is still indicative of an
averaged creatinine clearance of less than 20 ml/min and
since daily HD is of benefit to patients, it seems to be
advisable not to reduce dialysis dose at present.
As more details of the HEMO study results become
available it will be interesting to learn the width of the
confidence interval for the mortality risk at the higher-
dose level. It is possible that the observed risk for the
higher dose group in the HEMO study is consistent (i.e.,
overlapping) with the prior observation of a reduced
mortality risk. While the findings are reported as
consistent with no benefit from the higher dose, this
information may also be consistent with prior observa-
tions of a benefit.
The HEMO Study results were presented at the
American Society of Nephrology meeting in October
2002. The mortality risk for the high dose group
(mean eKt/V=1.53) versus the lower dose group (eKt/
V=1.16) was RR=0.96 and the 95% confidence
interval for this not-significant finding was 0.84 –1.10.
For this wide spread of the two dose groups, the more
HEMO STUDY IMPACT 15
recent observational studies would have estimated the
mortality RR to be 0.86. Since this value is within the
confidence interval of the HEMO Study, one can
conclude that the results of the HEMO Study agree
with both the null hypothesis (that higher does has no
effect) and the prior hypothesis (observational studies
that show a significant benefit to higher dose). Thus
more study is needed, including further exploration of
the HEMO Study. At this time we caution against a
dose reduction, as did some HEMO Study investiga-
tors during the discussion of their results.
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The presentation and publication of the results of the
HEMO study is a landmark event in the history of
hemodialysis (HD). This study is methodologically
sound and the investigators who carried it out are to be
congratulated. The results of the study have, however,
been surprising and even disturbing to many nephrolo-
gists. The notion that higher doses of HD lead to better
patientoutcomeshadbecomewidespread.Nowthere is a
need to pause and reconsider. This, however, is a good
process for our discipline to undergo. It leads us to
question our preconceived notions and it inspires us to
look for new ways of delivering better treatment.
How should this study influence our practice? This
question can be considered on two levels. First, there is
the question of how it should alter prescription of
conventional three times a week HD; second, is the
broader issue of whether alternative HD regimens may
be required to improve outcomes substantially. This
review addresses these two topics separately.
Prescription of Conventional HD
In conventional HD, the HEMO study tells us that
targeting a single-pool Kt/V of 1.25/treatment gives
outcomes just as good as targeting a higher value of 1.65.
Obviously all patients in our HD units should be
receiving at least the lower value of 1.25/treatment,
corresponding to a urea reduction of 65%.An important
question that arises, however, is howwe should deal with
the significant minority of patients who are already
receiving Kt/Vs ‡ 1.4/treatment. These patients are
typically those of below average body size with dialysis
times of 3.5–4.5 hours. Should we reduce their dialysis
times on the theory that outcomes will not be adversely
affected? After all, most patients do not wish to spend
any more time on HD than is required to maintain their
health. Such an approachwould therefore seem justified.
However, there are important caveats to consider
before treatment times are reduced. The HEMO study
did not directly examine the effect of time on patient
outcomes. Randomization was by clearance and flux
only. Inevitably, of course, the high-Kt/V group did
receive more dialysis time, but it is of interest that the
difference was only 30minutes. Thus the standard group
had a mean dialysis time of 3 hours, while the high-Kt/V
group had a mean of 3.5 hours. The surprisingly short
times required to achieve the higher Kt/V reflect the
relatively low body weight of patients who were eligible
for the HEMO study.
Therefore the study does not allow us to comment on
whether dialysis times of 4 hours or longer, as are used in
many countries, are superior to dialysis times of 3 hours.
Two decades ago the National Cooperative Dialysis
Study (NCDS) (1) addressed this issue. At that time the
investigators found, in a statistically very underpowered
study, that patients with longer treatment times (i.e., 4–5
hours) had borderline statistically significant better
outcomes than patients with shorter treatment times.
The concern inall this, obviously, is that dialysis time is
a surrogate for control of extracellular fluid volume and
thus blood pressure, and that this in turn may be critical
for cardiovascular outcomes. There is little doubt that
the contemporary HD population has markedly higher
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rates of cardiovascular disease and hypertension than
was the case at the timeof theNCDS.There is therefore a
significant concern that reductions in dialysis time may
adversely affect volume status, hypertension, and ulti-
mately patient outcomes. Notwithstanding all this, a
reasonable compromise might be as follows. Patients
who have a Kt/V in excess of 1.4/treatment could have
their dialysis time cautiously reduced if their blood
pressure is very well controlled and if their weight gains
aremodest. In this regard, goodbloodpressure control is
defined as readings consistently less than 135/85 mmHg.
Patients who do not fulfill these criteria risk having their
volume status and blood pressure adversely affected if
times are reduced.
NewHDpatients shouldbemodeled to achieve aKt/V
of 1.3/treatment, but the required time to reach this
target may not be sufficient to deal with fluid gains and
optimize volume status and blood pressure. The crucial
point here is that dialysis time should not be determined
solely by the need to achieve a given clearance target.
Rather it should also be strongly influenced by the need
to optimize volume status and bloodpressure control.Of
course, it is recognized that in many patients dialysis
treatment times of 4–5 hours are still not associated with
optimal blood pressure control. This highlights the need
to look at new paradigms for HD.
The Prescription for the Future?
The current treatment paradigm for HD of three
treatments per week each lasting 3–4 hours has been
followed almostworldwide for the past 25 years ormore.
This treatment prescription is not based on optimizing
physiology, but rather was developed as a compromise
between patient acceptance, what we knew about
adequacy of dialysis, and economic considerations, with
these three often moving in different directions. Patient
acceptance of HD treatment is marginal at best; the
treatment being plagued with intradialytic and postdia-
lytic symptoms, thus the patient often begs for a shorter
treatment. In some areas of the world, the economics
have also led to shorter treatments and adequacy might
be compromised. Such a compromise in turn may have
an adverse effect on population morbidity and mortality
statistics.
Even with the confusion following the HEMO study,
there must be at least a threshold for a delivered single-
poolKt/V (perhaps 1.25/treatment?) belowwhich results
in adverse outcome. There are many different ways to
influence the delivered dose of dialysis, for example, by
using dialyzers of different surface areas, varying blood
and dialysate flow rates, varying times of each treatment,
or perhaps using more frequent treatments. The ideal
treatment for renal failure would mimic the human
kidney and be both efficient and continuous.
Conventional HD is efficient but intermittent. By
contrast, peritoneal dialysis (PD) is continuous but
inefficient. While peritoneal treatments are often better
tolerated than those of HD with slow continuous fluid
and solute removal, they often do not provide adequate
dialysis, especially for larger patients. Whatever manip-
ulations that exist for improving the efficiency of PD,
they are ultimately limited by the surface area of the
peritonealmembrane and the volume that it can contain.
In contrast, HD can easily be improved by decreasing its
intermittence. Although not new in concept, there is
currently growing interest in daily HD.
Rational for Daily HD
The rationale for daily HD is based on the fact that
2 hours of dialysis performed only six times a week (total
12 hours), in theory, will significantly increase the weekly
removal of urea as compared to the corresponding
standard treatment regime of 4 hours three times a week.
Most of the urea removed (approximately 60%) during
a 4-hour dialysis takes place during the first half (2).
Therefore limiting the session to the first 2 hours will
decrease the removal capability by approximately 40%
each treatment, but it will produce a significant increase
when done on a weekly basis. Simple mathematics
indicate this to be by 20–40% (depending on 6 or 7 days
of treatment) for a standard efficiency dialyzer (urea
clearances of 150–200 ml/min).
The gain in terms of absolute global weekly removal
with short daily HD with respect to standard HD
increases progressively with the increase in the clearance
(efficiency) because it will increase the percentage
removal during the first 2 hours. Percentage removals
of up to 75% with a very high-efficiency dialyzer can be
attained (2), and again simple math indicates that the
global weekly removal with six times a week dialysis will
exceed that of standard HD by 50%. The gain by using
high-efficiency dialyzers in daily HD is indeed better
than with standard HD. With the latter, for example,
increasing the dialyzer clearance from 150 to 200ml/min
(a 33% increase of clearance) will be associated with an
approximate increase of 23% in weekly waste removal;
an equivalent 33% increment in clearance from 200 to
267 ml/min will only lead to a 16% increase in waste
removal (2). It is logical to conclude that it is advan-
tageous to use high clearances coupled with an increase
in frequency despite the reduction in the length of each
dialysis session.
In actual clinical practice the effect of this favorable
situation is blunted by the progressive decrease in
predialysis blood solute levels during the first 2–3
weeks of treatment, until a new steady state is reached.
Thus urea extraction will decline and weekly urea
removal will decrease until a new equilibrium is
established. This will be at a level that is more
advantageous for the patients since the predialysis
concentrations of solute, for example, urea, creatinine,
potassium, hydrogen ion, are reduced throughout the
week, as are the time-averaged concentrations of these
solutes and, perhaps of even more importance, the
time-averaged deviations in their concentrations. This
is particularly true with hydrogen ion and thus leads
to greatly improved control of acid-base equilibrium,
with blood levels of pH and bicarbonate remaining
very steady and within the normal range. As intradi-
alytic water removal is also easily performed without
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evidence of cardiovascular instability, the whole
‘‘unphysiology’’ of standard HD (3) is improved.
Although there is currently great interest in daily HD,
the idea is anything but new.The first description of daily
dialysis was in 1969 whenDePalma et al. (4) reported on
seven patients that had begun dialysis five times a week
for 4–5 hours per session the previous year. The reasons
for changing to more frequent dialysis included severe
intradialytic hypotension and severe interdialytic hyper-
tension. Both of these (and other medical problems for
which daily dialysis was used) were solved and all
patients experienced better appetite, weight gain, and
better biochemistries in spite of dietary restrictions being
lifted. DePalma et al.’s (4) daily dialysis program
continued into the early 1970s but was abandoned due
to a combination of reimbursement and technical
problems.
Between 1975 and 1981, Snyder et al. (5), Louis et al.
(6), and Manohar et al. (7) reported on a total of 10
patientsdialyzeddaily forperiods ranging from2months
to 7.5 years. These patients, previously dialyzed three
times a week for 15 hr/wk, were switched to 2 hours of
dialysis five times aweek.All observationsmade on these
patients were favorable, yet the programwas abandoned
in the mid 1980s again because of the U.S. dialysis
reimbursement schedule.
In 1979 Bonomini et al. (8) reported on six patients
dialyzed 6–12months for 3–4 hours 5 days aweek. These
patients had been placed on daily dialysis for a variety of
medical reasons, as well as severe subjective complaints,
all of which improved.
Since 1980, a slow but now accelerating growth in
investigators examining the concept of daily HD has
been led by Buonochristiani in Italy, Pierratos in
Canada, and Ting and Lockridge in the United States.
The largest number of patients with the longest obser-
vations of daily dialysis has come from Buonochristiani
et al. Starting in 1982, they have now treated close to 100
patients with an ongoing program.
A radically different approach to daily dialysis has
been taken by the Toronto group first led by the late
Robert Uldall and lately by Andreas Pierratos. The
Toronto program started in 1994 and they have used,
almost exclusively, long, slow overnight HD at home
with the patient dialyzing 5–7 nights a week. They have
reported on the excellent well being of their patients (9).
Ting et al. (10) usedbrief 1.5- to 2-hour daily dialysis as
a form of rescue therapy, treating a number of patients
with serious medical problems and dialysis intolerance.
They are treated six times a week in-center with
conventional dialysis equipment and have shown con-
siderable benefit, with in many cases, resolution of the
medical problems necessitating that form of therapy and
an improvement in quality of life. Additional reports
have come from Belgium, the Netherlands, France, and
other European centers as well as a number in North
America. Indeed, in North America there are currently
300 or more patients receiving mainly short daily HD
with some receiving long slow nocturnal dialysis (Lock-
ridge R, personal communication). A detailed review of
the literature is given by Kjellstrand and Ing (11) which
expands on the individual studies mentioned.
The London, Ontario Daily/Nocturnal HD Study
Despite the interest in daily HD, there are as yet no
randomized prospective studies comparing ‘‘hard’’
outcome data in patients dialyzed conventionally with
either the short daily or long slow nocturnal dialysis
methodologies. The London Study, the first to obtain
comparative data in this field, commenced in November
1998 and was completed by the end of 2001. It was a 3-
year observational study designed to compare 10
patients receiving short daily HD to 10 patients
receiving long slow nocturnal dialysis. All patients were
to be observed for at least 18 months and the treatments
were provided in the home environment. The choice of
an observational study was made deliberately because
of the anticipated impact of patient preferences regard-
ing the assigned arm of the experimental treatments.
Thus randomization would be fraught with difficulties
and certainly would influence patients’ quality of life.
All patients were studied in detail while still on
conventional HD and then serially while on the
experimental daily/nocturnal program. For each patient
selected for the study, a cohort control was obtained
matched as closely as possible for age, sex, comorbidity,
and the original dialysis modality (in-center HD,
satellite HD, self-care HD, home HD, or peritoneal
dialysis) and from the center in which that patient was
previously treated.
This investigation is now complete and its results
have been presented to the Ontario Ministry of Health
(the funding agency for the study). The study results,
in preparation for publication as a special supplement
to the American Journal of Kidney Diseases, show that
quotidian dialysis as compared with conventional
thrice-weekly HD provides improvement in a number
of physiologic areas without any evidence of harm. It
is associated with very significant improvement in the
patients’ perception of their quality of life. The
economic analysis of these home-based therapies is
entirely favorable and will be seen as financially
attractive to the Ministry of Health as well as other
providing agencies. The study group has therefore
recommended to the Ministry of Health that this
modality of treatment become a recognized form of
therapy and that an appropriate funding mechanism
be established. Specific recommendations in this regard
have been offered for consideration by the Ministry of
Health.
Future of Quotidian HD
It is the authors’ firm conviction that within a year a
number of Canadian provincial governments (respon-
sible for the delivery of health care) will create funding
mechanisms for this form of therapy. At that point there
will be a swing to this form of therapy, certainly in the
home setting, where cost-effectiveness is almost guaran-
teed. The question then becomes what percentage of the
total dialysis population will be managed in a home
environment. The London, Ontario, study has taken on
patients with significant comorbidities who were previ-
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ously being treated in in-center HDunits and has proven
that they canmanage at home.A conservative estimate is
that 20% of the total HD population will be able to
perform this therapy in the home environment. This
alone will have a huge impact on the health care
economics of renal replacement therapy.
This does not imply that daily dialysis will only be a
home therapy. Many patients who prefer daily HDmay
wish to remain in-center for various reasons, such as
inability to self-cannulate, vascular access, housing
restrictions, and others. High-risk patients with cramps,
hypotensive episodes, volume overload, and/or inter-
dialytic hypertensionmay benefit from five or six times a
week, short-hours, high-efficiencydialysis in the in-center
setting when it is logistically feasible. This might be done
on a permanent basis or on a temporary basis as a form
of ‘‘rescue therapy.’’
To accommodate these changes, in-center units will
have to alter their mind-sets regarding scheduling and
have improved dialysis equipment available for the
particular needs of daily dialysis. The development of an
‘‘in situ’’ reuse system of dialyzers and lines will be
of benefit not just economically but for patient conve-
nience. The overall improvement in well-being with
reductions in morbidity, hospitalizations, and the use of
erythropoietin and other medications will, over time,
show overall benefit to the end-stage renal disease
(ESRD) population.
These changes in dialysis practice are likely to become
morewidespread inCanadaandEurope longbefore they
are seen in the United States due to the peculiar reim-
bursement issues that many perceive stultify advance-
ment in the United States. The National Institutes of
Health (NIH) has shown initiative in recognizing the
growing swell of interest in daily dialysis by recently
holding a task forcemeeting. As usual, it is likely that the
NIH will want a randomized prospective study to com-
pare at least short-hours daily HD against conventional
therapy.Whether nocturnalHD can be studied is doubt-
ful since this is a home HD therapy, an area in which
there is currently little experience in the United States.
What would seem to be a reasonable approach would
be to set up a randomized prospective study of short-
hours daily HD versus three times a week, with each
group being assigned the same number of total hours
per week. The study should be carried out in-center on
patients with high morbidity scores and with high
complication rates so that the impact of the experimental
treatment on potential improvement is discernible within
a relatively short period of time.
Conclusion
The HEMO study has now shown us that conven-
tional three times a week HD targeting a single-pool
Kt/V greater than 1.25/treatment does not influence
outcome. Increasing the time of an intermittent therapy
is associated with diminishing returns in toxin removal,
but could be of benefit in volume control. The only way
to truly increase toxin removal is to increase the
frequency of the therapy. Even this may not explain the
benefits obtained by more frequent therapy. It could be
the approach to a more continuous state that provides
the benefit.
We cannot be complacent and say that there is no need
to seek out these benefits. The mortality rates of patients
undergoing HD, especially in North America, attest to
that.A change is needed and the time has come to look in
detail at daily HD. Reports going back as far as 1969
uniformly indicate benefit as compared to conventional
three times a week therapy.
To the protagonists, daily HD is seen as a cost-
effective form of therapy that is more physiologic
than conventional HD, and produces better outcomes
and improves the quality of life of dialysis patients.
The skeptics do not appear to doubt the theoretical
advantages of this form of therapy, but believe that
the increased frequency of dialysis treatment will be
unacceptable to patients and that major barriers exist
relating to bureaucratic and reimbursement issues.
Time will show them that once patients are exposed
to this form of therapy, they will never wish to return
to conventional HD. Bureaucracy will find, as a
minimum, that any increased expenditure has been
justified by increased well-being and even that, over
time, global costs are reduced.
References
1. Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of hemodialysis
prescription on patient morbidity: report from the National Cooperative
Dialysis Study. N Engl J Med 305:1176–1181, 1981
2. Buonocristiani U, Fagugli R, Quintaliani G, Kuluiranu H: Rationale for
daily dialysis.Home Hemodial Int 1:12–18, 1997
3. Kjellstrand CM, Evans RL, Peterson RJ, Shideman JR, von Hartitzsch B,
Buselmeier TJ: The ‘‘unphysiology’’ of dialysis: a major cause of dialysis side
effects? Kidney Int 7:S30–S34, 1975
4. DePalma JR, Pecker EA, Mazwell MHA: New automatic coil dialyzer
system for ‘‘daily’’ dialysis. Proc Eur Dial Transplant Assoc 6:26034, 1969
5. Snyder D, Louis BM, Gorfien P, Mordujovich J: Clinical experience with
long-term, brief, ‘‘daily’’ hemodialysis. Eur Dial Transplant Assoc 11:128–
135, 1975
6. Louis B, Patel TG, Pinedo A, Snyder D, Gorfein P: Clinical experience with
long-term 5 days-a-week hemodialysis.ProcDial Transplant Forum 5:58–60,
1975
7. Manohar NL, Louis BM, Gorfien P, Lipner HI: Success of frequent short
hemodialysis. Trans Am Soc Artif Intern Organs 27:604–609, 1981
8. Bonomini V, Mioli V, Albertazzi A, Scolari P: Daily-dialysis programme:
indications and results. Proc Eur Dial Transplant Assoc 9:44–52, 1972
9. Pierratos A, Ouwendyk M, Francoeur R, et al.: Nocturnal hemodialysis:
three year experience. J Am Soc Nephrol 9:859–868, 1998
10. Ting G, Freitas T, Saum N, Vas S, Raj DSC, Ecclestone A, Langos V,
Uldall R: Early metabolic, hematological, clinical and life quality changes
with daily hemodialysis. Perit Dial Int 18:S78, 1998
11. Kjellstrand CM, Ing T: History and revival of a superior dialysis method.
ASAIO J 44:117–122, 1998
HEMO STUDY IMPACT 19
Francesco Locatelli
Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy
During the last meeting of the National Kidney
Foundation (NKF) inChicago, the results of theHEMO
study were presented; they were, unfortunately, not as
expected. Themainobjective of the studywas to evaluate
the effect of the following interventions onmortality and
morbidity in four patient groups: high-flux versus low-
flux membranes and high versus standard dialysis dose
(Table 1). Further objectives included assessment of
cardiovascular hospitalization or death, infectious hos-
pitalization or death, nutritional status, comorbidity,
access-related problems, and quality of life. Patients had
tobeondialysis for‡3months andhavea serumalbumin
greater than 26 g/L. The observation period was up to 5
years, with substitution of dropout patients. Reuse of
dialyzers up to 20 times was allowed in the high-flux
group. The main characteristics of the enrolled patients
at the time of inclusion were mean age 58 years, mean
time on dialysis 3.7 years, mean spKt/V 1.6, mean serum
albumin 36 g/L; 60% of the patients were treated with
high-flux membranes.
The dialyzers used during the study for the low-flux
group were mainly the CA 210 and F8 and the CT 190
and F80 for the high-flux group. The Kt/V and urea
reduction rate (URR) values obtained in the standard
and high dialysis dose groups, respectively, were as
follows: spKt/V, 1.32 and 1.72; eqKt/V, 1.16 and 1.53;
and URR (%), 66 and 75. With regard to the primary
outcome, there were 440 deaths in the standard-dose
group and 431 in the high-dose group; 442 deaths
occurred in the low-fluxmembrane group and 429 in the
high-flux membrane group.
Considering the population as a whole, no effect of
higher dialysis dose was observed. In a subanalysis of
female patients, better survival was seen in the high-Kt/V
group (relative risk [RR]: 0.81; p ¼ 0.02), that is, a 19%
reduction in relative risk of mortality; in males, no
significant effect was found. For the patient population
as a whole, a slight statistically insignificant reduction in
mortality risk was observed in the high-flux group.
A subanalysis of those patients on dialysis for more
than 3.7 years revealed better survival in the high-flux
group (RR0.68;p ¼ 0.001),while forpatients ondialysis
for less than 3.7 years there was no effect at all. Thus
the answers were not as expected to the two questions: 1)
Does a dialysis dose above currently accepted mini-
mum levels improve the outcome of patients followed
up to 5 years? 2) Do high-flux membranes offer an
advantage independent of the dialysis dose?
In my opinion the main limitations of the HEMO
study lie in the fact that 60% of the enrolled patients
were previously treated with high-flux dialysis, and that
the mean spKt/V at the time of inclusion was relatively
high (a mean value of 1.6 ± 0.3). Therefore it is very
likely that some of the patients enrolled in the standard
dialysis dose group decreased their dose of dialysis, and
that patients previously on long high-flux dialysis were
enrolled in the low-flux dialysis group. Thus a carryover
effect may not be excluded. Moreover, the positive
selection of the patients surviving an average of 3.7 years
created a group not actually representing the dialysis
population. The mean age of the patients at inclusion in
the study was also far younger (58 years after an average
of 3.7 years on dialysis) than the general end-stage renal
disease (ESRD) population (61 years at the start of
dialysis); this should also be considered in the interpret-
ation of the data. Other factors influencing the repre-
sentativeness of the sample were the exclusion of
patients with plasma albumin £26 g/L, who have a
particularly high risk of morbidity and mortality and
who could possibly benefit more from intensive dialysis
(flux and Kt/V). Due to this positive selection of
patients, doubts on the general applicability of these
results are emerging.
One of the aims of the protocol was to compare the
effect of the dialyzer flux. However, the reuse practice
allowed by the protocol (up to 20 times) might have
changed the performance characteristics of the dialyzers
in a way that the differentiation between high flux and
lowflux, and consequently their effect onoutcome,might
become indistinct. It has been shown that CT190
(high flux), once reprocessed with Renalin, decreases
b2-microglobulin (b2M) clearance from a median of
about 42 to12ml/minafter 10 reuses (1).This last value is
very close to the upper limit of b2Mclearance selected for
the definition of low-flux dialyzers.
It is well known that the outcome of renal replacement
treatment is strongly related to the quality of care of the
predialysis period. Considering the long treatment time
on dialysis before randomization, it is possible that the
results of this clinical trial are only partially related to the
randomized treatment itself.Thedialysis ‘‘history’’might
well confound the effect of the intervention period,which
might be even shorter than the preceding period, thus
predialysis and prerandomization medical care could
also have had an effect on outcome.
In Europe, the Membrane Permeability Outcome
(MPO) study (2) is currently being performed in nine
countries and 61 study centers. Themain objective of this
study is to assess whether mortality is reduced with high-
flux dialysis as compared to low-flux dialysis. Patients
who are on dialysis for no longer than 2 months are
randomly allocated to high-flux or low-flux dialyzers.
The target patient number is 660 patients who have to be
observed for 3–6 years. As of this writing, the number of
randomized patients is 589; no substitution of dropout
patients is allowed and, according to European dialysis
practice, filter reuse is not allowed.
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The main differences between the HEMO and MPO
studies are that only new patients without dialysis
‘‘history’’ (incident patients) are included in the MPO
trial and only one intervention (membrane flux) is
evaluated. Moreover, in the MPO study there is no
exclusion of patients with low serum albumin (those
who might benefit more from high-flux dialysis), no
reuse of dialyzers is allowed, and dialysis prescription is
according to European practice (no attempt to minimize
treatment length).
The limitations of the HEMO study and the resultant
difficulties in interpreting its results underline the
importance of the MPO study. The hope is to come to
a more definitive conclusion on the effect of high-flux
membranes on patient outcomes.
In conclusion, it is undeniable that the HEMO study
results are very disappointing, considering that it has
been the opinion of most nephrologists that an increase
in the dose of HD, and the use of high-flux membranes,
could positively affect patient survival. This opinion has
been based mainly on the results of observational
evidence very recently supported by the preliminary
results ofDialysis Outcomes and Practice Patterns Study
(DOPPS). However, some of the noted drawbacks in the
HEMOstudy suggest that the study results should not be
considered conclusive. In fact, the general applicability of
the information coming from clinical trials may be
limited by the characteristics of the studied patients and
practice patterns. The differences between the HEMO
study (U.S. prevalent patients, substitution of the
dropouts, reuse of dialyzers, some exclusion criteria such
as low albumin levels) and the MPO study (European
incident patients, no substitution of the dropouts, no
dialyzer reuse) make the results of the ongoing MPO
study very important for clarifying the effect of mem-
brane flux on patient outcomes.
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TABLE 1. Patient groups
Standard double-pool
Kt/V 1.0–1.1, URR 65%
High double-pool
Kt/V 1.4–1.5, URR 75%
Low-flux membranes, b2M clearance < 10 ml/min A B
High-flux membranes, b2M clearance > 20 ml/min C D
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